Pore-cleansing agent

Abstract

To provide a pore improver that prevents troubles associated with visible pores, including blackheads, enlarged pores, sagging pores, and clogged keratin plugs, as well as pore inflammation-related troubles such as acne, while also enhancing the troubled skin condition.SOLUTION: A pore improver comprises a composition comprising a lipid membrane structure formed by phospholipids with an acid value of at least 5 mg KOH / g.SELECTED DRAWING: None

Description

Technical Field

[0003] , , , ,

[0001] The present invention relates to a pore-improving agent that forms a lipid membrane structure containing specific lipids.

Background Art

[0002] Pore-related skin problems such as prominent pores and acne are ranked among the top every year in various consumer surveys. For prominent pores, conventional care methods include physical removal of comedones using sheet packs or tools, tightening with astringents, and dissolution and removal of comedones using cleansing items containing solvents, surfactants, or scrubbing agents. These methods, despite imposing a large burden on the skin, have insufficient effects or only temporary effects limited to the application site. With each application, the burden on the skin accumulates, leading to further skin problems. Regarding acne, in recent years, acne caused by sudden changes in the skin environment or physical stimuli, known as mask dermatitis, has been increasing. Preventing acne is difficult, and once acne appears, it can only be treated by a doctor or with therapeutic drugs. However, this can lead to further skin problems such as scarring or dryness and rough skin caused by side effects of the therapeutic drugs. To date, as pore-improving agents for improving prominent pores and acne, for example, Patent Document 1 discloses a parakeratosis inhibitor, a pore-reducing agent, or a rough skin prevention / improvement agent composed of one or more compounds selected from the group consisting of specific β-alanine derivatives and their salts. Also, Patent Document 2 reports that the combined use of specific plant extracts and retinol-based components such as retinol and retinol derivatives can effectively improve the prominence of pores. On the other hand, Patent Document 3 reports that a lipid membrane structure mainly composed of phospholipids is useful for skin care as a carrier for active ingredients, but it is not known to be useful as a pore-improving agent.

Prior Art Documents

Patent Documents

[0003]

Patent Document 1

[0004] The pore-minimizing agents described in Patent Document 1 have insufficient efficacy from the active ingredient alone, and therefore, in human continuous use trials, high-concentration ethanol is used in combination. This presents problems as it makes the product unsafe for people with sensitive skin or skin problems, and also results in a long time for the effects to appear. Furthermore, the pore-improving composition described in Patent Document 2 has problems such as not being safe for people with sensitive skin or skin problems because it uses plant extracts extracted with high-concentration ethanol and retinol or its derivatives, which have a significant impact on the skin, and it takes a long time for the effects to appear. In view of the above circumstances, the problem that the present invention aims to solve is to provide a pore-improving agent that prevents one or more of the following problems: problems related to visible pores, such as blackheads, enlarged pores, sagging pores, and clogged pores, and problems related to inflammation of the pores, such as acne, and also improves the condition of the troubled pores. [Means for solving the problem]

[0005] As a result of diligent research, the inventors of this invention discovered that the above problems can be solved by using a lipid membrane structure formed from phospholipids having a specific acid value as a pore-improving agent, and thus completed the present invention.

[0006] In other words, the present invention is as follows. [1] A pore-improving agent comprising a composition containing a lipid membrane structure formed from phospholipids with an acid value of 5 mg KOH / g or higher. [2] The pore-improving agent according to [1] above, wherein the phospholipid is a hydrogenated phospholipid. [3] The pore-improving agent according to [1] or [2] above, wherein the lipid membrane structure is a single-layer lamellar structure. [4] The pore-improving agent according to [1] or [2] above, wherein the average hydrodynamic diameter of the lipid membrane structure is 200 nm or less. [5] A pore-improving agent as described in [1] or [2] above, which has a pore-reducing effect. [6] A pore-improving agent according to [1] or [2] above, which has an effect of regulating sebum secretion. [7] A pore-improving agent according to [1] or [2] above, which has the effect of lifting and removing keratin plugs, inhibiting keratin plug formation, or both. [8] A pore-improving agent according to [1] or [2] above, which has the effect of calming acne, suppressing acne development, or both. [9] A pore-improving agent as described in [1] or [2] above, which has the effect of improving blackheads in pores.

[10] A pore-improving agent as described in [1] or [2] above, which has the effect of improving makeup application, improving makeup longevity, or both. [Effects of the Invention]

[0007] The present invention provides a pore-improving agent that safely prevents one or more pore-related problems such as blackheads, enlarged pores, sagging pores, clogged pores, and acne, without requiring special treatments or medications, and also improves the condition of these problems with minimal burden on the skin. [Brief explanation of the drawing]

[0008] [Figure 1] This is a photograph of the lipid membrane structure formed in Example 5, observed using cryo-electron microscopy (Cryo-TEM). [Modes for carrying out the invention]

[0009] Hereinafter, embodiments for carrying out the present invention (hereinafter also referred to as "the present embodiments") will be described in detail. The present invention is not limited to the present embodiments, and can be variously modified and implemented within the scope of its gist.

[0010] The pore-improving agent of the present embodiment is a pore-improving agent containing a composition formed of a lipid membrane structure formed by a phospholipid having an acid value of 5 mg KOH / g or more (hereinafter also referred to as "lipid membrane structure-containing composition").

[0011] In the present specification, "lipid membrane structure" means particles having a lamellar (lipid bilayer) structure in which lipid molecules are arranged with hydrophilic groups facing outward and hydrophobic groups facing each other. Specific forms thereof include those described in the section of <lipid membrane structure-containing composition> described later. Also, in the present specification, for a lipid membrane structure-containing composition prepared using a composition for forming a lipid membrane structure, if the average hydrodynamic diameter can be measured using a dynamic light scattering measurement device, more specifically, a Zetasizer Nano ZSP (manufactured by Malvern Instruments), it is considered that a lipid membrane structure is formed.

[0012] <Composition for forming lipid membrane structure> The composition for forming a lipid membrane structure in the present embodiment is a composition for obtaining a lipid membrane structure-containing composition. Hereinafter, the components of the composition for forming a lipid membrane structure will be described.

[0013] [Component (A)] The composition for forming a lipid membrane structure in the present embodiment contains, as component (A), a phospholipid having an acid value of 5 mg KOH / g or more. The phospholipid having an acid value of 5 mg KOH / g or more may be one kind or two or more kinds, or may be a combination of one or more phospholipids having an acid value of less than 5 mg KOH / g and one or more phospholipids having an acid value of 5 mg KOH / g or more to make the acid value 5 mg KOH / g or more.

[0014] The origin of the phospholipid is not particularly limited, but it is preferably lecithin because it is of natural origin and can be suitably used in cosmetics and external skin preparations. Lecithin may be derived from soybeans, egg yolks, rapeseeds, sunflowers, corn, etc., and is preferably of plant origin such as soybeans, rapeseeds, sunflowers, corn, etc., and more preferably of soybean origin in terms of easy availability and quality stability.

[0015] As the phospholipid, from any one or more of the viewpoints of preventing oxidative degradation by the heating process in the production of cosmetics and quasi-drugs, preventing oxidative degradation during the storage of those products, and preventing the promotion of lipid oxidation in the stratum corneum and horny plugs around the pores where the phospholipid and its lipid membrane structure are oxidatively degraded, and maintaining and strengthening the structure of the intercellular lipids (barrier function) of the stratum corneum when the lipid membrane structure after application penetrates deep into the stratum corneum, and strengthening the barrier function of the lipid membrane formed on the skin by the lipid membrane structure remaining on the surface of the stratum corneum, it is preferably a hydrogenated phospholipid. The hydrogenated phospholipid can be obtained by adding hydrogen atoms to the unsaturated carbon bonds of the phospholipid by a conventionally known method. As the hydrogenated phospholipid, hydrogenated lecithin is particularly preferable.

[0016] The acid value of the phospholipid used in this embodiment is 5 mgKOH / g or higher. If a phospholipid with an acid value of less than 5 mgKOH / g is used, the dispersibility of the lipid membrane structure deteriorates, and a sufficient pore-improving effect cannot be obtained. From the viewpoint of obtaining a finer lipid membrane structure, the acid value of the phospholipid is preferably 6, 7, 8, 9, 10, or 11 mgKOH / g or higher, more preferably 12, 13, or 14 mgKOH / g or higher, even more preferably 15, or 16 mgKOH / g or higher, even more preferably 17, 18, or 19 mgKOH / g or higher, particularly preferably 20, or 21 mgKOH / g or higher, and particularly more preferably 22, 23, 24, 25, 26, or 27 mgKOH / g or higher. Furthermore, there is no particular upper limit to the acid value of the phospholipid, for example, 70 mgKOH / g or less, 60 mgKOH / g or less, 50 mgKOH / g or less, or 40 mgKOH / g or less. By appropriately selecting the type of phospholipid, it is possible to obtain phospholipids with the desired acid value. The acid value of the phospholipid shall be the value measured in accordance with "2006 Standards for Ingredients of Quasi-Drugs, General Test Methods, Section 27. Acid Value Measurement Method".

[0017] Either synthetic or commercially available phospholipids may be used. Examples of commercially available phospholipids include EMALEX® SLP manufactured by Nippon Emulsion Co., Ltd. and SLP-White H manufactured by Tsuji Oil Co., Ltd. These may be used individually or in combination of two or more.

[0018] The phospholipid content in the lipid membrane structure-forming composition in this embodiment is not particularly limited, but is preferably 5% by mass or more as a lower limit, and more preferably 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19% by mass or more. The upper limit is preferably 50% by mass or less, and more preferably 45, 40, 35, 30, 25, or 20% by mass or less. When the phospholipid content is 5% by mass or more, the lipid membrane structure is efficiently formed when the lipid membrane structure-forming composition is dispersed in water, and a sufficient pore improvement effect tends to be obtained. When the phospholipid content is 5% by mass or less, component (A) becomes more easily soluble or dispersed in the lipid membrane structure-forming composition, so by using the lipid membrane structure-forming composition, it becomes easier to form a lipid membrane structure with excellent dispersibility in the aqueous phase, and the long-term stability of the lipid membrane structure-containing composition tends to be increased.

[0019] [(B) Component] The lipid membrane structure-forming composition in this embodiment may contain a compound represented by the following formula 1 as component (B). Component (B) may consist of only one type or two or more types.

[0020] [ka]

[0021] In Formula 1 above, R is a substituted or unsubstituted alkyl group having 2 to 6 carbon atoms, or a substituted or unsubstituted cycloalkyl group having 3 to 6 carbon atoms.

[0022] C2-C6 alkyl groups may be linear or branched. Examples of C2-C6 alkyl groups include ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, iso-amyl group, tert-pentyl group, neopentyl group, n-hexyl group, 3-methylpentan-2-yl group, 3-methylpentan-3-yl group, 4-methylpentyl group, 4-methylpentan-2-yl group, 1,3-dimethylbutyl group, 3,3-dimethylbutyl group, and 3,3-dimethylbutan-2-yl group. C2-C6 alkyl groups are preferably linear. That is, C2-C6 alkyl groups are preferably groups selected from the group consisting of ethyl group, n-propyl group, n-butyl group, n-pentyl group, and n-hexyl group.

[0023] Examples of cycloalkyl groups having 3 to 6 carbon atoms include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl groups, with cyclohexyl being preferred.

[0024] The substituents on C2-C6 alkyl groups and C3-C6 cycloalkyl groups are not particularly limited as long as they do not hinder the effects of the present invention. Examples of substituents include halogen atoms, acyl groups, alkyl groups, aryl groups, alkoxyl groups, nitro groups, amino groups, and cyano groups. However, C2-C6 alkyl groups are not substituted with other alkyl groups.

[0025] In Formula 1 above, X is -O-, -C(=O)O-, or -OC(=O)-, preferably -O-. Also, in Formula 1 above, n is 0 or 1. In Formula 1 above, when X is -O- and n is 1, it is preferable that the number of carbon atoms in the alkyl group as R is 4 or more.

[0026] Component (B) is preferably at least one selected from the group consisting of, for example, 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, cyclohexylglycerin, and hexylglycerin.

[0027] In particular, when 1,2-hexanediol, 1,2-heptanediol, and hexylglycerin are used as component (B), an extremely fine lipid membrane structure can be formed. In this case, the lipid membrane structure is thought to form bicelles. Since bicelles are disc-shaped (disk-shaped) single-layer lamellar structures, they have superior penetration into the stratum corneum compared to liposomes of similar particle size. Therefore, from the viewpoint of obtaining a lipid membrane structure with high permeability of lipid-soluble components, it is preferable to use at least one selected from the group consisting of 1,2-hexanediol, 1,2-heptanediol, and hexylglycerin as component (B).

[0028] (B) Component may be either a synthetic product or a commercially available product.

[0029] The content of component (B) in the lipid membrane structure forming composition of this embodiment is not particularly limited, but is preferably 15% by mass or more as a lower limit, and more preferably 20, 25, 30, 35, 40, 45, or 50% by mass or more. As an upper limit, is preferably 95% by mass or less, more preferably 90, 85, 80, 75, or 70% by mass or less, and even more preferably 65, 60, or 55% by mass or less.

[0030] In the lipid membrane structure forming composition of this embodiment, the content of component (B) is preferably more than 100 parts by mass per 100 parts by mass of component (A). When the content of component (B) exceeds 100 parts by mass per 100 parts by mass of component (A), it tends to be easier to form a fine lipid membrane structure. Furthermore, the content of component (B) is preferably 110, 120, 130, 140, or 150 parts by mass or more per 100 parts by mass of component (A). When the content is 150 parts by mass or more, component (A) becomes more easily dissolved or dispersed in the lipid membrane structure forming composition, and therefore, by using this lipid membrane structure forming composition, it tends to be possible to form a lipid membrane structure with excellent dispersibility in the aqueous phase. Furthermore, from the viewpoint of obtaining a finer lipid membrane structure, the content of component (B) is preferably 160, 170, 180, 190, or 200 parts by mass or more, more preferably 210, 220, 230, 240, or 250 parts by mass or more, even more preferably 260, 270, 280, 290, or 300 parts by mass or more, even more preferably 310, 320, 330, 340, or 350 parts by mass or more, and particularly preferably 360, 370, 380, 390, or 400 parts by mass or more, per 100 parts by mass of component (A). On the other hand, there is no particular upper limit to the amount of component (B) per 100 parts by mass of component (A), but even if it exceeds 2000 parts by mass, it has little effect on the solubility or dispersibility of component (A) in the lipid membrane structure forming composition and is uneconomical. Therefore, it is preferable that the amount of component (B) be 2000 parts by mass or less per 100 parts by mass of component (A). Accordingly, according to this embodiment, the amount of component (B) is preferably more than 100 parts by mass and 2000 parts by mass or less per 100 parts by mass of component (A).

[0031] [(C) component] The lipid membrane structure-forming composition of this embodiment may further contain water as component (C). When using component (A) with a high acid value, by using components (B) and (C) in combination, a lipid membrane structure-forming composition with superior solubility or dispersibility of component (A) can be obtained, and by using this lipid membrane structure-forming composition, it tends to be possible to form a lipid membrane structure with excellent dispersibility in the aqueous phase. In addition, component (C) plays a role in assisting the incorporation of component (D) (basic compound) and component (E) (acidic compound) into the lipid membrane structure-forming composition. Specifically, by pre-dissolving component (D) and / or component (E) in component (C) and then mixing them with components (A) and (B), component (D) and / or component (E) can be easily incorporated into the lipid membrane structure-forming composition.

[0032] (C) Component is preferably water with few impurities, for example, purified water which is purified from ordinary water by a system such as ion exchange, distillation, reverse osmosis, or ultrafiltration, either alone or in combination.

[0033] The content of component (C) in the lipid membrane structure forming composition of this embodiment is not particularly limited, but is preferably 0.5% by mass or more as a lower limit, more preferably 1, 2, 3, 4, or 5% by mass or more, even more preferably 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15% by mass or more, and particularly preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25% by mass or more. The upper limit is preferably 75% by mass or less, more preferably 70, 65, or 60% by mass or less, even more preferably 55, 50, 45, or 40% by mass or less, and particularly preferably 35 or 30% by mass or less.

[0034] Furthermore, in the lipid membrane structure forming composition of this embodiment, the mass ratio (B) / (C) of component (B) to component (C) is preferably 0.3 to 100. The lower limit of this mass ratio range may be 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0. The upper limit of this mass ratio range may be 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, or 6. The mass ratio range is more preferably 0.5 to 9, and even more preferably 1.0 to 6.

[0035] [(D) component] The lipid membrane structure-forming composition of this embodiment may further contain a basic compound as component (D). When using component (A) with a high acid value, by including component (D), it is possible to obtain a lipid membrane structure-forming composition with superior solubility or dispersibility of component (A), and using such a lipid membrane structure-forming composition tends to improve the dispersibility of the lipid membrane structure in the aqueous phase. Component (D) may be one type or two or more types.

[0036] Examples of component (D) include inorganic bases such as sodium hydroxide, potassium hydroxide, and ammonia; basic amino acids such as arginine, lysine, and histidine; and amine compounds such as ethanolamine, diethanolamine, triethanolamine, 2-amino-2-methyl-1,3-propanediol (AMPD), and 2-amino-2-hydroxymethyl-1,3-propanediol (tromethamine). Among these, arginine is preferred.

[0037] (D) Component may be either a synthetic or commercially available product.

[0038] The content of component (D) in the lipid membrane structure forming composition of this embodiment is not particularly limited, but is preferably 0.01% by mass or more, and more preferably 0.02% by mass or more, as a lower limit. It is preferably 2% by mass or less, and more preferably 1% by mass or less, as an upper limit.

[0039] In the lipid membrane structure forming composition of this embodiment, the content of component (D) is preferably 0.05 parts by mass or more, and more preferably 0.1 parts by mass or more, per 100 parts by mass of component (A). The upper limit is preferably 10 parts by mass or less, and more preferably 5 parts by mass or less.

[0040] [(E) component] The lipid membrane structure-forming composition of this embodiment may contain an acidic compound as component (E). By including component (E), a lipid membrane structure-forming composition with superior solubility or dispersibility of component (A) can be obtained, and using such a lipid membrane structure-forming composition tends to improve the dispersibility of the lipid membrane structure in the aqueous phase. Component (E) may be one type or two or more types.

[0041] Examples of component (E) include inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, and carbonic acid; and organic acids such as acetic acid, formic acid, propionic acid, butyric acid, citric acid, lactic acid, succinic acid, malic acid, tartaric acid, pyrrolidone carboxylic acid (PCA), gluconic acid, benzoic acid, ethylenediaminetetraacetic acid (EDTA), etidronic acid, pentetic acid, and phytic acid. Among these, organic acids are preferred from the viewpoint of obtaining a lipid membrane structure-forming composition that is superior in solubility or dispersibility of component (A).

[0042] In particular, from the viewpoint of obtaining a lipid membrane structure-forming composition with superior solubility or dispersibility of component (A), forming a lipid membrane structure with excellent dispersibility in the aqueous phase using the lipid membrane structure-forming composition, and improving the storage stability of the lipid membrane structure-forming composition and the lipid membrane structure-containing composition using the lipid membrane structure-forming composition, component (E) is preferably an organic acid with chelating properties. Component (A) may have a tendency to bind with metal ions. In this case, by adding an organic acid with chelating properties as component (E), metal ions in the lipid membrane structure-forming composition are captured, improving the storage stability of the lipid membrane structure-forming composition, and making component (A) more easily soluble or dispersed, thereby obtaining a lipid membrane structure-forming composition with superior solubility or dispersibility of component (A). It is presumed that by using this composition, a lipid membrane structure with excellent dispersibility in the aqueous phase and storage stability can be formed. Preferred organic acids with chelating properties include, for example, citric acid, ethylenediaminetetraacetic acid (EDTA), etidronic acid, and pentetic acid, with ethylenediaminetetraacetic acid (EDTA) being more preferred.

[0043] Component (E) may be either a synthetic or commercially available product.

[0044] In the lipid membrane structure forming composition of this embodiment, the content of component (E) (in terms of free acid) is not particularly limited, but is preferably 0.02% by mass or more, and more preferably 0.04% by mass or more, as a lower limit. It is preferably 4% by mass or less, and more preferably 2% by mass or less, as an upper limit.

[0045] In the lipid membrane structure forming composition of this embodiment, the content of component (E) (in terms of free acid) is preferably 0.1 parts by mass or more, and more preferably 0.2 parts by mass or more, per 100 parts by mass of component (A). The upper limit is more preferably 20 parts by mass or less, and more preferably 10 parts by mass or less.

[0046] From the viewpoint of increasing the solubility of components (D) and (E) in the lipid membrane structure-forming composition and keeping the pH of the composition within a predetermined range when dispersed in the aqueous phase, the lipid membrane structure-forming composition of this embodiment preferably contains both components (D) and (E). Such a lipid membrane structure-forming composition may be obtained by adding components (D) and (E) separately, or by adding salts of components (D) and (E).

[0047] The salts of components (D) and (E) are not particularly limited, but examples include lysine hydrochloride; sodium citrate salts such as trisodium citrate; sodium phosphate salts such as disodium hydrogen phosphate; sodium benzoate; sodium ethylenediaminetetraacetate salts such as trisodium ethylenediaminetetraacetate (EDTA-3Na); and sodium diethylenetriaminepentaacetate salts such as pentasodium diethylenetriaminepentaacetate (pentetate 5Na).

[0048] When the lipid membrane structure-forming composition contains component (D) and component (E), the mass ratio (D) / (E) of component (D) and component (E) is 0.2 to 10. The lower limit of this mass ratio range may be 0.3, 0.4, or 0.5. The upper limit of this mass ratio range may be 10, 9, 8, 7, 6, or 5. The mass ratio range is preferably, for example, 0.5 to 5.

[0049] In the lipid membrane structure forming composition of this embodiment, the total content of component (D) and component (E) is preferably 0.05% by mass or more, more preferably 0.1% by mass or more, as a lower limit. As an upper limit, it is preferably 4% by mass or less, and more preferably 2% by mass or less.

[0050] [(F) component] The lipid membrane structure-forming composition of this embodiment may further contain a lipid-soluble compound as component (F). When using component (A) with a high acid value, by using components (B) and (F) in combination, a lipid membrane structure-forming composition with superior solubility or dispersibility of component (A) can be obtained, and by using this lipid membrane structure-forming composition, it is possible to form a lipid membrane structure with excellent dispersibility in the aqueous phase and high storage stability. Furthermore, by using component (F) in combination with the above-mentioned components (D) and / or (E), it is possible to form a finer lipid membrane structure. Component (F) may be one type or two or more types.

[0051] (F) Examples of components include sterols such as phytosterols, cholesterol, phytosteryl / octyldodecyl lauroyl glutamate, phytosteryl oleate, and phytosteryl glucoside; triterpenes such as γ-oryzanol, glycyrrhizic acid, ursolic acid, and Centella asiatica extract (a mixture of asiatic acid, madecassic acid, and asiaticoside); fat-soluble vitamins such as retinol, hydrogenated retinol, cholecalciferol, tocopherol, and ascorbic acid esters; and astaxanthin. Examples include carotenoids such as β-carotene; coenzymes such as ubiquinone; hydrocarbons such as limonene, petrolatum, and squalane; ceramides such as ceramide EOS, ceramide NG (ceramide 2), ceramide NP (ceramide 3), ceramide AP (ceramide 6II), ceramide EOP (ceramide 1), dihydroxylignoceroylphytosphingosine, cerebroside, sphingoglycolipids, and cetyl PG hydroxyethyl palmitamide; and polyphenols such as tetrahydrodiferuloylmethane and pterostilbene. In particular, from the viewpoint of obtaining a lipid membrane structure-forming composition that has superior solubility for component (A), allows for easy incorporation of component (F), and has good storage stability by combining component (F), component (A), and component (B), it is preferable that component (F) is at least one selected from the group consisting of phytosterols, cholesterol, γ-oryzanol, glycyrrhizic acid, ursolic acid, Centella asiatica extract (a mixture of asiatic acid, madecassic acid, and asiaticoside), hydrogenated retinol, tocopherol, astaxanthin, ubiquinone, ceramide NG, ceramide NP, ceramide AP, ceramide EOP, tetrahydrodiferuloylmethane, and pterostilbene.

[0052] (F) Component may be either a synthetic or commercially available product. Examples of commercially available products include phytosterol-SKP from Tama Biochemical Co., Ltd., TECA from Bayer AG, dl-α-tocopherol from DSM Corporation, NIKKOL® retinol H10, NIKKOL® VC-IP, and squalane from Nikko Chemicals Co., Ltd., astaxanthin-20C and γ-oryzanol from Oryza Oil & Fat Chemical Co., Ltd., Kaneka Coenzyme Q10 from Kaneka Corporation, CERAMIDE2 from Croda Japan Co., Ltd., and ursolic acid 90%, Sabi White, and Ptero White from Sabinsa Japan Corporation.

[0053] The content of component (F) in the lipid membrane structure forming composition of the present invention is not particularly limited, but is preferably 0.001% by mass or more, more preferably 0.01% by mass or more, even more preferably 0.1% by mass or more, and particularly preferably 1% by mass or more. The upper limit is preferably 12% by mass or less, more preferably 10% by mass or less, even more preferably 8% by mass or less, and particularly preferably 6% by mass or less.

[0054] Furthermore, in the lipid membrane structure forming composition of this embodiment, the content of component (F) is preferably, at a lower limit, 0.005 parts by mass or more, more preferably 0.05 parts by mass or more, even more preferably 0.5 parts by mass or more, and particularly preferably 5 parts by mass or more, per 100 parts by mass of component (A). At an upper limit, it is preferably 60 parts by mass or less, more preferably 50 parts by mass or less, even more preferably 40 parts by mass or less, and particularly preferably 30 parts by mass or less.

[0055] [Other ingredients] The lipid membrane structure-forming composition of this embodiment may further contain components other than those listed above (A) to (F). These other components are not particularly limited and include oils, surfactants, humectants, whitening agents, colorants, alcohols, amino acids, sugars, vitamins, viscosity modifiers, polymers, colorants, powders, UV absorbers, preservatives, antibacterial agents, antioxidants, fragrances, beauty ingredients, electrolytes, fibers, plant extracts, etc. These may be used individually or in combination of two or more. For example, by incorporating beauty ingredients such as humectants and whitening agents into the lipid membrane structure-forming composition and dispersing the composition in an aqueous phase, a lipid membrane structure containing the beauty ingredients can be formed. The timing of incorporating the beauty ingredients is not particularly limited when forming a lipid membrane structure containing the beauty ingredients. For example, a lipid membrane structure-forming composition containing ingredients other than cosmetic ingredients may be prepared and stored, and when preparing a lipid membrane structure-containing composition, cosmetic ingredients may be added to the lipid membrane structure-forming composition, uniformly dissolved, and then dispersed in the aqueous phase to form a lipid membrane structure containing cosmetic ingredients. This means that the lipid membrane structure-forming composition not only simplifies the production of individual pore-improving agents, but also allows for the easy creation of different product groups by stocking the lipid membrane structure-forming composition in advance and arbitrarily changing the cosmetic ingredients it contains.

[0056] From the viewpoint of obtaining a finer lipid membrane structure, the pH when the lipid membrane structure-forming composition is dispersed in the aqueous phase is preferably 4.0 or higher, more preferably 5.0 or higher, even more preferably 7.0 or higher, and even more preferably 8.0 or higher. On the other hand, from the viewpoint of obtaining a lipid membrane structure with a uniform particle size (i.e., a lipid membrane structure-containing composition with high uniformity), the pH when the lipid membrane structure-forming composition is dispersed in the aqueous phase is preferably 10.0 or lower, more preferably 9.5 or lower, and even more preferably 9.0 or lower. In other words, the lipid membrane structure-forming composition of this embodiment preferably has a pH of 4.0 to 10.0 when dispersed in the aqueous phase. Here, "pH when the lipid membrane structure-forming composition is dispersed in the aqueous phase" refers to the pH of the product obtained by dispersing the lipid membrane structure-forming composition in the aqueous phase, and is measured by the following method. Add 100 mL of purified water to a 200 mL beaker to prepare the aqueous phase. Heat the aqueous phase to 80°C and add the prepared lipid membrane structure-forming composition at 80°C while stirring at 100 rpm. After the addition is complete, stir at 80°C for 2 minutes to prepare the lipid membrane structure-containing composition. Allow the prepared lipid membrane structure-containing composition to cool naturally to room temperature (25°C), and measure the pH at 25°C using a glass electrode pH meter (HM-25R, manufactured by Toa DKK Co., Ltd.).

[0057] <Composition containing lipid membrane structure> The lipid membrane structure-containing composition in this embodiment is a composition containing a lipid membrane structure formed from phospholipids with an acid value of 5 mg KOH / g or higher, and can be obtained using the lipid membrane structure-forming composition described above. However, as long as the composition contains a lipid membrane structure formed from phospholipids with an acid value of 5 mg KOH / g or higher, it will exhibit the effect of a pore-improving agent in this embodiment, and the manufacturing method is not particularly limited, and known methods can be used. For example, a fine single-layer lamellar structure may be prepared using the sonication method, ethanool injection method, or cholic acid removal method, or a fine lipid membrane structure may be prepared by combining a high-pressure emulsifier such as a microfluidizer or a micronization method such as the extrusion method in a method for preparing a lipid membrane structure including a multilayer lamellar structure, such as the Bangham method or polyhydric alcohol method. When forming a lipid membrane structure using such known methods, the composition is not limited to the above-described lipid membrane structure-forming composition, except that it contains phospholipids with an acid value of 5 mg KOH / g or higher as a component constituting the lipid membrane structure, and the process may be carried out using components and steps suitable for each manufacturing method.

[0058] The morphology of the lipid membrane structure is not particularly limited as long as it has a lamellar (lipid bilayer) structure in which lipid molecules are arranged with their hydrophilic groups facing outward and their hydrophobic groups facing inward, and examples include liposomes, bicelles, and α-gels. The lipid membrane structure may be a single-layer lamellar structure called a unilamella or single lamellar, a multi-layer (2 to 10 layers) lamellar structure called an oligolamella, or a multi-lamellar structure with more layers, and these may be mixed. The lipid membrane structure is preferably a single-layer lamellar structure. Single-layer lamellar structures have a fine particle size and excellent compound encapsulation efficiency and permeability. The fact that the lipid membrane structure is a single-layer lamellar structure can be confirmed, for example, using cryo-electron microscopy (Cryo-TEM). In this embodiment, the lipid membrane structure is preferably a single-layer lamellar liposome. Single-layer lamellar liposomes have a fine particle size and a high internal aqueous phase volume, and therefore have excellent compound encapsulation efficiency and permeability. Therefore, it is useful in pore-improving agents that contain water-soluble beauty ingredients. Furthermore, in this embodiment, the lipid membrane structure is preferably a bicell. A bicell is a fine, disc-shaped, single-layer lamellar structure with a thickness of 3 to 10 nm and a diameter of 15 to 100 nm, and it has excellent encapsulation efficiency and penetration of lipid-soluble components. Therefore, it is useful in pore-improving agents that contain lipid-soluble beauty ingredients. In the lipid membrane structure-containing composition of this embodiment, only one of single-layer lamellar liposomes and bicells may be present, or these two may be mixed together.

[0059] The upper limit of the average hydrodynamic diameter of the lipid membrane structure is preferably 200 nm or less, and more preferably 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, or 80 nm or less, from the viewpoint of dispersibility, storage stability, and skin penetration. The lower limit of the average hydrodynamic diameter of the lipid membrane structure is not particularly limited, but from the viewpoint of the efficiency of forming a single-layer lamellar structure, it is, for example, 20 nm or more.

[0060] The upper limit of the polydispersity index (PDI) of the lipid membrane structure is preferably 0.80 or less, more preferably 0.50 or less, even more preferably 0.40 or less, even more preferably 0.30 or less, even more preferably 0.25 or less, and particularly preferably 0.20 or less, from the viewpoint of dispersibility, storage stability, and skin penetration. The lower limit of the polydispersity index (PDI) of the lipid membrane structure is not particularly limited, but for example, it is 0.01 or more.

[0061] The mean hydrodynamic diameter and polydispersity index (PDI) of the lipid membrane structure shall be determined using a dynamic light scattering analyzer (Malvern Instruments, Zetasizer Nano ZSP), employing the harmonic mean diameter (Z-Average) and polydispersity index (PDI) based on scattered light intensity obtained through cumulant analysis. The definitions of mean hydrodynamic diameter and polydispersity index used herein shall conform to those described in "JIS Z8828:2019 Particle size analysis - Dynamic light scattering method".

[0062] From the viewpoint of obtaining a sufficient pore-improving effect, the concentration of the lipid membrane structure in the lipid membrane structure-containing composition is preferably 0.0001% by mass or more, more preferably 0.01% by mass or more, and even more preferably 1% by mass or more. On the other hand, there is no particular upper limit to the concentration, but for example, it is less than 5% by mass.

[0063] The pH of the lipid membrane structure-containing composition is preferably 4.0 to 10.0. Specifically, this pH is determined by using a pH meter (HM-25R, manufactured by Toa DKK Co., Ltd.) measured by the glass electrode method.

[0064] <Method for producing a lipid membrane structure-containing composition> The method for producing the lipid membrane structure-containing composition of the present invention is not particularly limited. When forming a lipid membrane structure using known methods, the method may be carried out using components and steps suitable for each production method, except that the lipid membrane structure contains phospholipids with an acid value of 5 mg KOH / g or more as components constituting the lipid membrane structure. Furthermore, when using the above-described lipid membrane structure-forming composition, the method may involve adding a large excess of water to the lipid membrane structure-forming composition obtained by mixing component (A) above with (B) to (F) and other components as desired, or adding the lipid membrane structure-forming composition to a large excess of water. From the viewpoint of improving the dispersibility of the lipid membrane structure, the latter method is preferred. That is, in the method for producing the lipid membrane structure-containing composition according to this embodiment, it is preferable to disperse the lipid membrane structure-forming composition obtained by mixing component (A) above with (B) to (F) and other components as desired in an aqueous phase.

[0065] More specifically, the method for producing the lipid membrane structure-containing composition in this embodiment preferably comprises the steps of: mixing component (A) with one or more components selected from the group consisting of components (B), (C), (D), (E), (F), and other components as needed to obtain a lipid membrane structure-forming composition (mixing step); and dispersing the lipid membrane structure-forming composition in an aqueous phase (dispersion step).

[0066] (Mixing process) In the mixing process, each component may be mixed all at once or sequentially. When mixing the components sequentially, the order is not particularly limited. For example, when preparing a composition for forming a lipid membrane structure using components (A), (B), and (C), components (A) and (B) may be mixed first, then component (C) may be added and mixed; or components (A) and (C) may be mixed first, then component (B) may be added and mixed; or components (B) and (C) may be added to component (A) simultaneously (for example, by adding a mixed solvent of components (B) and (C)) and then mixed. Also, for example, when preparing a composition for forming a lipid membrane structure using components (C), (D), and / or (E) in addition to components (A) and (B), components (C), (D), and / or (E) may be added separately, or the mixture may be added after being mixed beforehand. Furthermore, when preparing a composition for forming a lipid membrane structure using components (A), (B), and (F) above, in addition to components (C), (D), and / or (E), the order in which component (F) is added is not particularly limited. For example, after mixing components (A), (B), and (F), components (C), (D), and / or (E) may be added simultaneously or sequentially. Alternatively, after mixing components (A) and (B), components (C), (D), and / or (E) simultaneously or sequentially, component (F) may be added last. Moreover, when preparing a composition for forming a lipid membrane structure using the components described in [Other Components] above, the order in which the components described in [Other Components] above are added is not particularly limited and can be appropriately selected, for example, depending on their solubility. For example, if they are lipid-soluble, they may be added together with component (F) or added last. Alternatively, if it is water-soluble, it may be added together with components (C), (D), and / or (E), or added last.

[0067] The mixing temperature when mixing each component is not particularly limited, but is preferably above the phase transition temperature of component (A). For example, the upper limit is 120, 110, 100, 95, or 90°C, and the lower limit is 40, 45, 50, 55, 60, 65, 70, 75, 80, or 85°C. For example, it is 40 to 120°C, preferably 40 to 100°C, and more preferably 60 to 90°C. The mixing time is also not particularly limited, but is preferably 10 to 180 minutes. The mixing method is not particularly limited, but since it does not require high mechanical shear force, it can be carried out using known mixing means such as a magnetic stirrer (e.g., a hot stirrer), a paddle mixer, a propeller mixer, or a planetary mixer.

[0068] In the mixing process, in addition to the mixing of each component described above, other processes such as purification (e.g., filtration), cooling, and storage may be carried out as appropriate. For example, a mixture may be prepared by mixing component (A) and component (B) with (C) to (F) and some of the other components as desired. After removing any undissolved material from the mixture by filtration, the mixture may be cooled and stored. Then, when preparing the lipid membrane structure-containing composition, the remaining (B) to (F) and other components may be added to the mixture as needed to obtain a lipid membrane structure-forming composition.

[0069] (Dispersion process) The dispersion of the lipid membrane structure-forming composition obtained by the mixing step into the aqueous phase may be carried out without stirring the aqueous phase (adding the lipid membrane structure-forming composition to the aqueous phase), while stirring the aqueous phase, or by adding the aqueous phase to the lipid membrane structure-forming composition, since the lipid membrane structure-forming composition spontaneously forms a fine lipid membrane structure even without substantial mechanical shear force. In this case, the stirring conditions for the aqueous phase and / or the lipid membrane structure-forming composition are not particularly limited, but for example, known stirring means can be used at a rotation speed of 10 to 300 rpm. Furthermore, the lipid membrane structure-forming composition and / or the aqueous phase may be added all at once, added in portions, or added sequentially at any rate using known dropping means.

[0070] For the aqueous phase, it is preferable to use water with few impurities. For example, it is preferable to use purified water, which has been purified from ordinary water by a system that uses ion exchange, distillation, reverse osmosis, or ultrafiltration, either alone or in combination. Furthermore, the aqueous phase may contain components other than water, as long as the formation of a lipid membrane structure is possible. Examples of components other than water include oils, surfactants, humectants, whitening agents, colorants, alcohols, amino acids, sugars, vitamins, viscosity modifiers, polymers, colorants, powders, UV absorbers, preservatives, antibacterial agents, antioxidants, fragrances, beauty ingredients, electrolytes, fibers, plant extracts, etc.

[0071] In the dispersion process, the temperature of the aqueous phase is preferably above the phase transition temperature of component (A) because this tends to lead to efficient formation of the lipid membrane structure. The temperature of the aqueous phase can be, for example, an upper limit of 100, 95, or 90°C, and a lower limit of 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60°C. The temperature of the aqueous phase can be, for example, 0 to 100°C, preferably 25 to 100°C, more preferably 40 to 95°C, and even more preferably 60 to 90°C.

[0072] In the dispersion step, the temperature of the lipid membrane structure-forming composition to be dispersed is preferably above the phase transition temperature of component (A) because this tends to lead to efficient formation of the lipid membrane structure. The temperature of the lipid membrane structure-forming composition is, for example, an upper limit of 120, 110, 100, 95, or 90°C, and a lower limit of 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60°C. The temperature of the lipid membrane structure-forming composition is, for example, 0 to 120°C, preferably 25 to 120°C, more preferably 40 to 100°C, and even more preferably 60 to 90°C.

[0073] In the method for producing the lipid membrane structure-containing composition according to this embodiment, in addition to the mixing and dispersion steps described above, other steps such as purification (e.g., filtration), cooling, and storage may be further performed.

[0074] <Pore-improving agent> The lipid membrane structure-containing composition of this embodiment may be used as a pore-improving agent as is, or it may be incorporated into cosmetics or topical skin preparations to impart a pore-improving effect.

[0075] The form of the pore-improving agent in this embodiment is not particularly limited as long as the lipid membrane structure is stably incorporated, but examples include lotion, gel, emulsion, cream, shampoo, and facial cleanser. From the viewpoint of taking advantage of the transparency of appearance, penetration upon application, and high stability due to the inclusion of a fine lipid membrane structure (for example, an average hydrodynamic diameter of 200 nm or less) in this embodiment, it is preferable to incorporate it into a low-viscosity lotion where it is difficult to incorporate the lipid membrane structure.

[0076] In addition to the lipid membrane structure-containing composition described above, the pore-improving agent of this embodiment may further contain ingredients commonly used in cosmetics or topical skin preparations, to the extent that they do not impair the effects of the present invention. Examples of such ingredients include, but are not limited to, oils, surfactants, moisturizers, whitening agents, colorants, alcohols, amino acids, vitamins, viscosity modifiers, polymers, colorants, powders, UV absorbers, preservatives, antibacterial agents, antioxidants, fragrances, beauty ingredients, electrolytes, pH adjusters, fibers, water, and plant extracts.

[0077] In the pore-improving agent containing the lipid membrane structure composition of this embodiment, the concentration of the lipid membrane structure is preferably 0.0001% by mass or more, more preferably 0.01% by mass or more, and even more preferably 1% by mass or more. On the other hand, there is no particular upper limit to the concentration, but for example, it is less than 5% by mass.

[0078] The pore-improving effects are not particularly limited to those that improve pore-related problems. Examples include pore-reducing effects for pores that are noticeable in shape, such as enlarged pores and sagging pores; sebum secretion regulation effects; lifting / shedding of comedones and suppression of comedone formation, or both; calming acne and suppressing acne outbreaks, or both; improvement of blackheads in pores; and improvement of makeup application and makeup longevity, or both.

[0079] Furthermore, the pore-improving effect includes either an immediate effect, a continuous effect, or both. An immediate effect refers to the appearance of the effect starting 1 to 30 minutes, preferably 3 to 20 minutes, and more preferably 5 to 15 minutes, after applying the pore-improving agent to the skin. A continuous effect refers to the appearance of the effect starting 1 day to 1 month, preferably 3 days to 3 weeks, and more preferably 5 days to 2 weeks, after continuously applying the pore-improving agent to the skin twice a day, morning and evening, and the effect being maintained or even enhanced as application continues thereafter. [Examples]

[0080] The present invention will be described in more detail using examples and comparative examples, but the present invention is not limited in any way by these examples. In the following examples, unless otherwise specified, all operations were carried out at room temperature (20-25°C). Unless otherwise specified, "%" and "parts" mean "mass%" and "parts by mass," respectively.

[0081] <Preparation of lipid membrane structure-containing composition> A lipid membrane structure-containing composition was prepared by the following method. Lecithin was prepared by obtaining several commercially available hydrogenated and unhydrogenated soybean-derived lecithins with different acid values ​​(acid values ​​from 0.3 to 30.8 mg KOH / g) and mixing them in proportions to achieve the desired acid value. The following six types of hydrogenated and unhydrogenated soybean-derived lecithins were used. Hydrogenated lecithin, acid value 0.3 mg KOH / g Hydrogenated lecithin, acid value 6.1 mg KOH / g Hydrogenated lecithin, acid value 15.0 mg KOH / g Hydrogenated lecithin, acid value 20.0 mgKOH / g Hydrogenated lecithin, acid value 23.1 mg KOH / g Unhydrogenated lecithin, acid value 17.0 mgKOH / g

[0082] [Examples 1-7, Comparative Examples 1-2] A composition for forming a lipid membrane structure was obtained by heating components (A) to (F) shown in Table 1 (the unit of content is parts by mass) to 80°C and mixing them uniformly. A composition containing a lipid membrane structure was obtained by adding the above lipid membrane structure-forming composition to component (G) heated to 80°C, mixing it uniformly, and then cooling it. In Comparative Example 2, unmixed oil droplets were present when components (A) to (F) were mixed, resulting in a non-uniform solution. Furthermore, the composition mixed with the aqueous phase appeared cloudy, and the formation of a lipid membrane structure could not be confirmed.

[0083] [exterior] The lipid membrane structure-containing compositions prepared in the examples and comparative examples were visually observed at 25°C in 3.7 cm diameter glass bottles, and their appearance was evaluated based on the following criteria (◎ or ○ indicates good dispersibility of the lipid membrane structure): ◎: The liquid is transparent or semi-transparent, allowing the text on the opposite side of the container to be visible. ○: The writing on the opposite side of the container is not visible, but it is a uniform liquid. ×: Separation or precipitation may be observed.

[0084] [Presence or absence of lipid membrane structure formation] The lipid membrane structure-containing compositions prepared in the examples and comparative examples were observed using a transmission electron microscope (Hitachi High-Technologies H-7650) via Cryo-TEM, and the presence or absence of lipid membrane structure formation was evaluated based on the following criteria (◎ or ○ indicates that a lipid membrane structure has been formed): ◎: Monolayer lamellar liposome structures and bicelle structures are observed. ○: In addition to monolayer lamellar liposome structures and bicelle structures, multilayer lamellar liposome structures are observed. ×: No lipid membrane structure observed.

[0085] [Average hydrodynamic diameter, polydispersity index (PDI)] The average hydrodynamic diameter and polydispersity index (PDI) of the lipid membrane structure were measured by cumulant analysis using a dynamic light scattering analyzer (Malvern Instruments, Zetasizer Nano ZSP).

[0086] Figure 1 shows a cryo-TEM image of the lipid membrane structure-containing composition obtained in Example 5. The ring-shaped images represent monolayer lamellar liposome structures, and the rod-shaped images represent bicelle structures, confirming the formation of a monolayer lamellar lipid membrane structure.

[0087] [Pore Improvement Effect Test] Using the lipid membrane structure-containing compositions obtained in the examples and comparative examples as samples, 20 expert panelists (women in their 20s to 50s) conducted efficacy tests a to h below, and the effects compared to before application were evaluated by sensory assessment based on the following criteria. ◎: Very effective ○: Effective NAGONA: No change ×: Condition worsens a [Immediate pore-minimizing effect] Each sample was applied to the skin, and the pore-reducing effect was evaluated after 10 minutes. b [Continuous pore-minimizing effect] Each sample was applied to the skin twice a day, morning and evening, and the pore-reducing effect was evaluated after one week. c[Spontaneous lifting and shedding of blackheads] Each sample was applied to the skin twice a day, morning and evening, and the spontaneous lifting and shedding of keratin plugs within one week was evaluated. d [Sebum secretion regulating effect] At night, each sample was applied to the skin, and its effect on regulating sebum secretion upon waking the following morning was evaluated. e [Effect of inhibiting keratin plug formation] Each sample was applied to the skin twice a day, morning and evening, and the effect of inhibiting keratin plug formation was evaluated after one week. f[Improvement effect on blackheads in pores] Each sample was applied to the skin twice a day, morning and evening, and the effect on improving blackheads in pores was evaluated after one week. g[Immediate improvement in makeup application] Each sample was applied to the skin in the morning, and its effect on improving makeup application was evaluated. [Continuous improvement in makeup application] Each sample was applied to the skin twice a day, morning and evening, and the effect on improving makeup application after one week was evaluated. i[Improves makeup longevity] Each sample was applied to the skin in the morning, and its effect on improving makeup longevity throughout the day was evaluated. j[Soothing effect on acne] Each sample was applied to areas with acne twice a day, morning and evening, and the effect of spontaneously calming the acne within one week was evaluated. k [Effect of suppressing acne breakouts] Each sample was applied to the skin twice a day, morning and evening, and the effect of suppressing the frequency of acne breakouts was evaluated over a period of four weeks from the start of application.

[0088] The results for each of the above evaluations are shown in Table 1 below.

[0089] [Table 1]

[0090] As shown in Table 1, the compositions of Examples 1 to 7, which dispersed lipid membrane structures formed from hydrogenated and unhydrogenated lecithin with an acid value of 5 mg KOH / g or higher, showed pore-improving effects such as immediate pore reduction, continuous pore reduction, spontaneous keratin plug lifting and shedding, sebum secretion regulation, keratin plug formation inhibition, improvement of blackheads, immediate improvement of makeup application, continuous improvement of makeup application, improvement of makeup longevity, acne soothing effect, and acne occurrence inhibition effect. On the other hand, Comparative Example 1 used hydrogenated lecithin with an acid value of less than 5 mg KOH / g, and although the formation of a lipid membrane structure was confirmed, the pore-improving effect was not sufficient. Comparative Example 2 used hydrogenated lecithin with an acid value of 5 mg KOH / g or higher, but due to the excessive inclusion of squalane, an O / W emulsion was formed instead of a lipid membrane structure, and the pore-improving effect was not sufficient.

Claims

1. A pore-improving agent comprising a composition containing (A) a hydrogenated phospholipid derived from soybeans with an acid value of 5 mg KOH / g or more and (B) 1,2-pentanediol, wherein the content of component (B) exceeds 100 parts by mass of a lipid membrane structure relative to 100 parts by mass of component (A), The aforementioned lipid structure, when dispersed in the aqueous phase, spontaneously disperses as a lipid structure with an average hydrodynamic diameter of 200 nm or less. A pore-improving agent that has one or more pore-improving effects selected from the group consisting of pore-reducing effect, sebum secretion regulation effect, comedone lifting / detachment effect, comedone formation inhibition effect, acne-soothing effect, acne occurrence inhibition effect, blackhead improvement effect, makeup application improvement effect, and makeup longevity improvement effect.

2. The pore-improving agent according to claim 1, wherein the lipid membrane structure is a single-layer lamellar structure.

Images